Press Release

Cambridge, Mass. (June 1, 2022) – Remix Therapeutics (Remix), a biotechnology company developing small molecule therapies designed to reprogram RNA processing and address the underlying drivers of disease, today announced that Peter Smith, Ph.D., Co-Founder and Chief Executive Officer of Remix, will present a corporate overview at the Jefferies Healthcare Conference on Wednesday, June 8, 2022, at 4:30 p.m. ET in New York.

A live webcast of the presentation may be accessed here and on the News & Media section of the Remix website. A replay of the webcast will be available for approximately 90 days following the presentation.

About Remix Therapeutics

Remix Therapeutics is a biotechnology company developing novel small molecule therapies designed to reprogram RNA processing and treat disease in entirely new ways. The REMaster technology platform makes it possible to identify patterns in RNA processing and exploit them to modulate gene expression. Remix’s innovative therapeutic approach has the ability to alter the way genes are read from the genome, to correct, enhance, or eliminate the gene message, thereby addressing disease drivers at their origin. For more information visit www.remixtx.com.

Contacts:

Media Contact:

Lissette Steele
lsteele@vergescientific.com
202-930-4762 ext. 409

Investor Contact:

Will O’Connor  
Stern Investor Relations 
will.oconnor@sternir.com  
212-362-1200  

Supports Novel Small Molecule Therapeutic Approach Designed to Reprogram RNA Processing and Modulate Gene Expression

Cambridge, Mass. (May 17, 2022) – Remix Therapeutics (Remix), a biotechnology company developing small molecule therapies designed to reprogram RNA processing and address the underlying drivers of disease, today announced the close of a $70 million Series B financing. Surveyor (a Citadel company) joined the Series B syndicate alongside existing investors Foresite Capital, Atlas Venture, The Column Group, Arch Venture Partners, Alexandria Venture Investments, and Casdin Capital. The funds will support development of the company’s REMaster technology platform and advancement of a pipeline of RNA processing targeted therapeutics.

“We are pleased to announce this Series B financing that reflects the significant progress we have made to advance our novel platform and programs modulating RNA processing. With the support of our new and existing investors, we will continue on our path to address disease drivers at their origin,” said Peter Smith, Ph.D., Co-Founder and Chief Executive Officer of Remix Therapeutics. “This financing will support further development of our REMaster platform, which enables the design of molecules that can selectively degrade RNA, enhance RNA expression, induce exon skipping, or rescue genetic lesions. This technology will transform how diseases are treated.”

Fueled by its proprietary technology platform, Remix is leveraging the power of data analytics, bespoke high-throughput screening technologies, and next generation chemistry to advance a pipeline of breakthrough therapies. The company’s innovative approach has the unique ability to precisely identify and target RNA processing steps to enhance or eliminate protein function, or to correct dysregulation in disease.

“Drug discovery has primarily centered on targeting proteins but many genetically validated disease mechanisms and targets remain unaddressed. Alternate approaches to building new medicines are needed, so we are thrilled to support Remix’s mission to create a new set of tools to not only treat disease in new ways, but to treat diseases more effectively,” said Michael Rome, PhD, Managing Director at Foresite Capital.

Remix recently entered into a strategic collaboration with Janssen Pharmaceutica NV, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, for the discovery and development of small molecule therapeutics that modulate RNA processing using Remix’s REMaster drug discovery platform.

About Remix Therapeutics

Remix Therapeutics is a biotechnology company developing novel small molecule therapies designed to reprogram RNA processing and treat disease in entirely new ways. The REMaster technology platform makes it possible to identify patterns in RNA processing and exploit them to modulate gene expression. Remix’s innovative therapeutic approach has the ability to alter the way genes are read from the genome, to correct, enhance, or eliminate the gene message, thereby addressing disease drivers at their origin. For more information visit www.remixtx.com.

Contacts:

Media Contact:

Lissette Steele
lsteele@vergescientific.com
202-930-4762 ext. 409

Investor Contact:

Will O’Connor  
Stern Investor Relations  will.oconnor@sternir.com  
212-362-1200  

Highlights Potential for Novel RNA-Targeted Therapeutics 

Cambridge, Mass. (March 30, 2022) – Remix Therapeutics (Remix), a biotechnology company developing small molecule therapies designed to modulate RNA processing and address the underlying drivers of disease, today announced the publication of an article titled “Reprogramming RNA Processing: An Emerging Therapeutic Landscape,” in the peer-reviewed journal Trends in Pharmacological Sciences. The article, co-authored by Christopher R. Neil, Ph.D., Anant A. Agrawal, Ph.D., and colleagues at Remix Therapeutics, provides an overview of RNA processing events and the role they play in gene regulation, with a particular focus on the therapeutic opportunities that have emerged within this landscape. The article can be accessed here.

“At Remix, we are leading the development of a new wave of medicines that seek to target RNA processing to achieve therapeutic activity against targets that are difficult to drug,” said Zaven Kaprielian, Ph.D., Chief Scientific Officer of Remix Therapeutics. “Our REMaster platform allows us to systematically target discrete RNA processing events. We are delighted to have this exciting therapeutic approach highlighted in this review.”

The paper’s authors noted that, “As knowledge around these regulatory processes continues to evolve alongside advances in RNA-based platforms and technologies, it is likely that an ever-increasing set of diseases will become accessible for the development of a new wave of therapeutics.”

About Remix Therapeutics

Remix Therapeutics is a biotechnology company developing novel small molecule therapies designed to reprogram RNA processing and treat disease in entirely new ways. The REMaster technology platform makes it possible to identify patterns in RNA processing and exploit them to modulate gene expression. Remix’s innovative therapeutic approach has the ability to alter the way genes are read from the genome, to correct, enhance, or eliminate the gene message, thereby addressing disease drivers at their origin. For more information visit www.remixtx.com.

Contacts:

Media Contact:
Lissette Steele
lsteele@vergescientific.com
202-930-4762 ext. 409

Investor Contact:
Will O’Connor  
Stern Investor Relations 
will.oconnor@sternir.com  
212-362-1200  

Cambridge, Mass. (March 24, 2022) – Remix Therapeutics (Remix), a biotechnology company developing small molecule therapies designed to modulate RNA processing and address the underlying drivers of disease, today announced that management will participate in one-on-one meetings with investors at the SVB Leerink Biopharma Private Company Connect being held virtually from March 29-31, 2022.

About Remix Therapeutics

Remix Therapeutics is a biotechnology company developing novel small molecule therapies designed to reprogram RNA processing and treat disease in entirely new ways. The REMaster technology platform makes it possible to identify patterns in RNA processing and exploit them to modulate gene expression. Remix’s innovative therapeutic approach has the ability to alter the way genes are read from the genome, to correct, enhance, or eliminate the gene message, thereby addressing disease drivers at their origin. For more information visit www.remixtx.com.

Contacts:

Media Contact:
Lissette Steele
lsteele@vergescientific.com
202-930-4762 ext. 409

Investor Contact:
Will O’Connor  
Stern Investor Relations 
will.oconnor@sternir.com  
212-362-1200  

Cambridge, Mass. (March 16, 2022) – Remix Therapeutics (Remix), a biotechnology company developing small molecule therapies designed to reprogram RNA processing and address the underlying drivers of disease, today announced an upcoming presentation at the RNA Leaders World Congress taking place March 16-17, 2022 in Basel, Switzerland.

Title: Small molecule modulation of mRNA processing to control gene expression and target disease drivers
Presenter: Peter Smith, Ph.D., Co-Founder and Chief Executive Officer of Remix Therapeutics
Date and Time: Thursday, March 17 at 4:20 PM CET

Dr. Smith’s presentation will highlight mechanisms of mRNA processing regulation and advances in the drug discovery toolkit that are leading to novel insights for small molecule discovery. Remix is developing small molecule therapies designed to reprogram RNA processing and address the underlying drivers of disease. For more information, please visit the RNA Leaders World Congress website here.

About Remix Therapeutics

Remix Therapeutics is a biotechnology company developing novel small molecule therapies designed to reprogram RNA processing and treat disease in entirely new ways. The REMaster technology platform makes it possible to identify patterns in RNA processing and exploit them to modulate gene expression. Remix’s innovative therapeutic approach has the ability to alter the way genes are read from the genome, to correct, enhance, or eliminate the gene message, thereby addressing disease drivers at their origin. For more information visit www.remixtx.com.

Contacts:

Media Contact:

Lissette Steele
lsteele@vergescientific.com
202-930-4762 ext. 409

Investor Contact:

Will O’Connor  
Stern Investor Relations 
will.oconnor@sternir.com  
212-362-1200